Citigroup reiterated coverage on Aldeyra Therapeutics with a new price target
$ALDX
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup reiterated coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $21.00 from $25.00 previously